Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs GoodRx
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict68/ 100
Grade C · #185GoodRx
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.
Visit GoodRxThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 68/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. GoodRx still earns its place — shoppers who want self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results69
92
Real-world results69
97Price honesty62
97
Price honesty62
96Prescriber access92
96
Prescriber access92
88Formulary choice66
88
Formulary choice66
95Cancellation fairness56
95
Cancellation fairness56
93Member support60
93
Member support60
Price, coverage & features
| Metric | CoreAge Rx | GoodRx |
|---|---|---|
| Verdict Score | 94/100 | 68/100 |
| Grade | A | C |
| Semaglutide | $149/mo | Not disclosed |
| Tirzepatide | $349/mo | From $299/mo (brand Zepbound) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | No | No |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
GoodRx
What we like
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
The caveats
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers who want self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies.
Visit GoodRx Read the full GoodRx review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programmes closest to it, and the same shortlist for GoodRx does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.